Guardians of Drug Safety

Editor’s Note: “Every drug can be made, and every disease can be treated.” Since 2000, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision. 

In tribute to the journey, we look back through the eyes of our “dream-makers”: revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.

The first time Dr. Robert Zhang realized the power of toxicology, it wasn’t in a textbook or a lab notebook, but in a conference room.

A small molecule for postpartum depression had just cleared its final round of review. Years earlier, the program had stumbled on toxicity data that nearly halted development. But Zhang, then a young toxicologist, saw a path forward. Through painstaking study design and reevaluation, his team helped the company reframe its safety data and prove the drug’s potential.

Months later, at a meeting with patients and their families, Zhang listened as new mothers described how the therapy had lifted them from the fog of depression. “Their gratitude,” he says, “made every late-night data review worth it.”

That moment crystallized for him what toxicology really means: not just testing for harm, but safeguarding hope.

From Toxicologist to Enabler

A veterinarian by training and a neuroscientist by passion, Zhang has spent more than two decades studying how medicines interact with biology. 

Today, as Global Head of Toxicology at WuXi AppTec, Zhang brings that same scientific rigor and curiosity to an even larger landscape: a global, integrated CRDMO platform spanning research, development, and manufacturing.

“Toxicology is the sentinel of drug development,” he says. “We are the guardians at the gate, ensuring safety, accelerating progress, and preventing costly failures downstream.”

At WuXi AppTec, Zhang leads one of Asia’s largest GLP (Good Laboratory Practice) toxicology networks, with state-of-the-art facilities totaling nearly a million square feet. Yet scale alone, he insists, isn’t what creates “WuXi Speed.”

“Speed without quality is meaningless,” he says. “What matters is how we design every study scientifically, precisely, and transparently, so that results can stand anywhere in the world.”

His teams draw on experience across regulatory frameworks from the FDA, EMA, and NMPA. Every protocol undergoes multi-layered review; every dataset is verified before submission. “A study report must not only be fast, it must be flawless,” Zhang explains. “That’s how our clients earn approvals faster and sleep better at night.”

Automation has also transformed how toxicology runs. WuXi AppTec’s proprietary scheduling and visualization system tracks hundreds of studies simultaneously, optimizing animal use, staff allocation, and data integrity. “We built an automated platform that sees every variable before it becomes an error,” Zhang says. “That’s what allows speed and quality to coexist.”

A Partner from Molecule to Market

Within WuXi AppTec’s integrated ecosystem, toxicology is not an isolated checkpoint: it is a connected arc of science that begins as early as molecule discovery. 

“Our work is not a transaction,” Zhang says. “It’s a relationship that often spans the entire life of a molecule.”

WuXi AppTec’s toxicology teams work side-by-side with DMPK, bioanalysis, biology, CMC, and regulatory experts from the very first experiments. Results from early screening flow seamlessly into toxicology study design, minimizing rework, reducing handoff errors, and accelerating decisions.

This continuity, Zhang emphasizes, is one of the platform’s greatest strengths. For many molecules, especially novel modalities like peptides, oligonucleotides, or their conjugates, traditional toxicity playbooks may no longer apply. Each molecule may require customized assays, specialized analytical methods, or unique species selection. Having the biology team that helped discover the molecule only a hallway away from the toxicology team that will evaluate it creates a level of coherence few organizations can achieve.

In practice, this means WuXi AppTec does far more than run studies. When a client brings in a complex or first-in-class molecule, particularly one without established toxicology precedents, the toxicology team shapes the assay strategy, determines the appropriate species and dose-escalation logic with the customer, and ensures the study is aligned with the intended development path. 

Zhang recalls a recent program for a rare-disease molecule that offered few regulatory precedents to guide its development. To meet that challenge, WuXi AppTec assembled toxicology team leaders and senior pathology experts to design a tailored evaluation strategy grounded in the molecule’s structural features for the client. The result was a toxicology package that cleared FDA review smoothly, and within the client’s targeted submission window, demonstrating how finding the solution together accelerates progress without compromising rigor. 

“Clients choose us because our quality is consistent, our communication is transparent,” Zhang says. “Our collaboration is built on partnership.”

Trust, he adds, is earned over time. Zhang recalls one long-time partner, a biotech whose molecule, shepherded through WuXi AppTec’s non-clinical pipeline, became the first of its kind approved in the U.S. “They’ve worked with us for thirteen years,” he says with quiet pride. “At one point, they told us: ‘You’re the only partner who delivers faster than our expectations—without ever cutting corners.’”

Preparing for the Future of Toxicology

The field of toxicology is undergoing a quiet but profound shift. Regulatory agencies are encouraging reduction of animal use, and new scientific tools are rapidly maturing. Zhang sees this not as disruption, but evolution.

For years, toxicology relied primarily on animal models. But, as he notes, no animal can perfectly reflect human biology. The future lies in creating multi-model, human-relevant prediction systems, where animal data, in vitro data, and -omics data reinforce each other.

Rather than one model simply replacing another, Zhang envisions a more precise and humane system built from complementary parts: one type of model will anchor the most human-relevant biology; other studies will be applied selectively where they are most predictive, and results generated will continuously flow back to refine every model and assumption. “We are preparing for a world where safety prediction is faster, more accurate, and more human-centered,” he says. “That is where the field is going, and we are already preparing for it.”

Every Patient Deserves Safe Medicine

As the industry moves toward human-relevant testing, Zhang envisions WuXi AppTec’s toxicology unit as both innovator and bridge-builder, linking regulatory science with discovery, technology with humanity.

“Our vision, ‘Every drug can be made, and every disease can be treated,’ is not just a slogan,” he says. “For us, it means every program deserves a fair chance, and every patient deserves a safe medicine. If we do our job right, no therapy will be held back due to incomplete safety knowledge.”

He pauses thoughtfully, recalling that toxicology review meeting years ago and the women whose lives changed because a young toxicologist refused to give up on a risky idea.

“That,” he says softly, “is why I still love this work.”